Results 241 to 250 of about 620,136 (263)

NK cell dysfunction in antiphospholipid syndrome. [PDF]

Front Immunol
Martirosyan A, Kriegova E, Manukyan G.
europepmc   +1 more source

Correction to: SYK negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy. [PDF]

J Immunol
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma

Ca-A Cancer Journal for Clinicians, 2022
Elshad Hasanov, Marion Smits, Priscilla K Brastianos   +2 more
exaly  

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

Ca-A Cancer Journal for Clinicians, 2023
Balazs Dome
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023
Rujul Parikh
exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Victoria Metaxa, Elie Azoulay   +2 more
exaly  

The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management

Ca-A Cancer Journal for Clinicians, 2020
Enrica Marchi
exaly  

Oral cavity and oropharyngeal squamous cell carcinoma—an update

Ca-A Cancer Journal for Clinicians, 2015
Angela C Chi
exaly  

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly